^
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive
:
A2